The unanswered question: when to initiate antiretroviral therapy in children with HIV infection

被引:3
|
作者
Abrams, Elaine J. [1 ,2 ]
机构
[1] Columbia Univ, Harlem Hosp Ctr, New York, NY USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Programs, New York, NY USA
关键词
antiretroviral therapy; CD4; pediatrics; treatment guidelines; viral load;
D O I
10.1097/COH.0b013e3282cef1ee
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review The question of when to initiate antiretroviral treatment for children is perhaps the most critical unanswered question in pediatric HIV therapeutics. With large numbers of children throughout the world acquiring HIV infection and with improved global access to HIV treatment it is particularly timely to consider the optimal time to initiate antiretroviral therapy in infants, children and adolescents. Recent findings Early treatment can result in suppression of HIV viremia, immune preservation and prevention of disease progression. This must be balanced by the challenges of maintaining adherence to multidrug regimens, the risks of selecting drug-resistant virus, and long and short-term toxicities of medications. Summary This review provides a framework within which to consider when to initiate children on antiretroviral treatment. A child's age and developmental status, where they live, and the goals and expectations for treatment provide a context for balancing the risks of disease progression with the risks of drug-related toxicities and viral resistance.
引用
下载
收藏
页码:416 / 425
页数:10
相关论文
共 50 条
  • [21] NEUROPATHOLOGICAL EFFECTS OF ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-1 INFECTION
    CHO, ES
    MINTZ, M
    EPSTEIN, LG
    SHARER, LR
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1993, 52 (03): : 270 - 270
  • [22] Antiretroviral therapy and mortality among children with perinatal HIV infection - Reply
    Pezzotti, P
    Rezza, G
    Balducci, M
    Tovo, PA
    Gabiano, C
    Galli, L
    de Martino, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (22): : 2871 - 2872
  • [23] Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: Implications for when to initiate therapy
    Wang, CL
    Vlahov, D
    Galai, N
    Bareta, J
    Strathdee, SA
    Nelson, KE
    Sterling, TR
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (06): : 1046 - 1054
  • [24] Dual antiretroviral therapy for HIV infection
    Soriano, Vicente
    Vicente Fernandez-Montero, Jose
    Benitez-Gutierrez, Laura
    de Mendoza, Carmen
    Arias, Ana
    Barreiro, Pablo
    Pena, Jose M.
    Labarga, Pablo
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 923 - 932
  • [25] Antiretroviral therapy and management of HIV infection
    Volberding, Paul A.
    Deeks, Steven G.
    LANCET, 2010, 376 (9734): : 49 - 62
  • [26] Update of antiretroviral therapy for HIV infection
    Nadler, JP
    Oehler, RL
    Holt, D
    INFECTIONS IN MEDICINE, 1998, 15 (02) : 113 - 116
  • [27] Combination antiretroviral therapy for HIV infection
    Maenza, J
    Flexner, C
    AMERICAN FAMILY PHYSICIAN, 1998, 57 (11) : 2789 - 2798
  • [28] Antiretroviral therapy in patients with HIV infection
    Bartlett, JG
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (03) : 172 - 179
  • [29] Universal Antiretroviral Therapy for HIV Infection?
    Lundgren, Jens D.
    Wood, Robin
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) : 888 - 890
  • [30] ANTIRETROVIRAL THERAPY OF HIV-INFECTION
    JOST, J
    LUTHY, R
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1991, 121 (16) : 555 - 565